5 results
The objective of this investigation is to describe visual outcomes and assess the safety at 12 months (330 - 420 days) post bilateral implantation of the AcrySof® IQ PanOptix* Presbyopia correcting IOL Model TFNT00.
Primary Objective:To evaluate the long-term safety and tolerability of eptinezumab in patients with chronic cluster headache (cCH)Secondary ObjectivesTo evaluate the efficacy of eptinezumab in patients with cCHExploratory ObjectiveTo explore the…
To find a suitable treatment option for the 25% of HS patients who are therapy-resistant. Additionally, we expect a faster healing time of the wounds, meaning that even if patients respond to current treatment, HBOT may improve their quality of life…
Primary Objective• To evaluate the efficacy of eptinezumab as add-on to BI for the prevention of migraine and treatment of MOHSecondary Objectives• To evaluate the efficacy of eptinezumab as add-on to BI on health-related quality of life and work…
Primary Objective:- To evaluate the efficacy of eptinezumab in patients with eCHSecondary Objectives:- To evaluate the efficacy of eptinezumab on health-related quality of life, health care resource utilization, and work productivitySafety…